Mounjaro Cuts Heart Attack Risk by 33% in New Study

New research indicates that Mounjaro, a medication used for type 2 diabetes and obesity, may significantly lower the risk of heart attacks in patients also living with heart disease. A study involving nearly 53,000 participants found a 33% reduction in heart attack likelihood for those taking Mounjaro compared to another diabetes drug, sitagliptin. The analysis, published in The BMJ, tracked major adverse cardiovascular events and revealed that Mounjaro users experienced a lower incidence of these events.

Beyond cardiac protection, the study suggested Mounjaro also helps prevent hospital admissions due to infections and reduces deaths from any cause. Researchers estimate that for every 70 people treated, one heart attack case could be prevented. These findings provide valuable evidence for shared decision-making in patient care, highlighting potential cardiovascular benefits.

However, the use of GLP-1 receptor agonists, including Mounjaro (tirzepatide) and semaglutide (Ozempic, Wegovy), has also been associated with reports of hair loss. Regulatory bodies in the US and the UK have received numerous reports linking these drugs to alopecia. For instance, the UK's MHRA noted hundreds of hair loss reports for tirzepatide in the past year, alongside significant numbers for semaglutide.